Atreca, a US-based, immune system-focused drug developer that counts pharmaceutical firm GlaxoSmithKline (GSK) as an investor, closed a $35m series B round today.
Investment management firm Wellington Management Company co-led the round with an undisclosed US-based, healthcare-focused fund, most likely the same one that led Atreca’s $56m series A round in late 2015.
The series B round also featured hedge fund sponsor Cormorant Asset Management and unnamed new and existing investors. GSK, Mission Bay Capital and Bill and Melinda Gates Foundation had all participated in the series A.
Atreca is developing therapeutics that are based on the antibodies, T cell receptors and targets involved with human immune responses, and is particularly concentrating on cancer. It will use the series B funds to further develop its pipeline of antibody-based drugs.
Tito A. Serafini, co-founder and CEO of Atreca, said: “This funding enables us to accelerate the acquisition of immune response data central to cancer immunotherapy and to expand and advance our pipeline of novel antibody therapeutics based on those data.”